Current through Bulletin 2024-18, September 15, 2024
Under Subsection
58-17b-601(1),
guidelines for providing patient counseling in Section
58-17b-613 include the
following:
(1)
(a) Counseling shall be offered orally in
person, unless the patient or patient's agent is not at the pharmacy or a
specific communication barrier prohibits oral communication.
(b) Counseling may be provided through a
telepharmacy system.
(2)
A pharmacy facility shall orally offer to counsel, but is not required to
counsel a patient or patient's agent who refuses counseling.
(3) Based upon the professional judgment of
the pharmacist, pharmacy intern, or DMP, patient counseling may include the
following elements:
(a) name and description
of the prescription drug;
(b)
dosage form, dose, route of administration and duration of drug
therapy;
(c) intended use of the
drug, when known, and expected action;
(d) special directions and precautions for
preparation, administration and use by the patient;
(e) common severe side or adverse effects or
interactions and therapeutic contraindications that may be encountered,
including their avoidance, and the action required if they occur;
(f) techniques for self-monitoring drug
therapy;
(g) proper
storage;
(h) prescription refill
information;
(i) action to be taken
in the event of a missed dose;
(j)
pharmacist comments relevant to the individual's drug therapy, including any
other information specific to the patient or drug; and
(k) the date after which the prescription
should not be taken or used, or the beyond use date.
(4) The offer to counsel shall be documented.
Documentation shall be maintained for five years, and be available for
inspection by the Division within seven to ten business days of the Division's
request.
(5) Only a pharmacist,
pharmacy intern, or DMP may orally provide counseling to a patient or patient's
agent and answer questions concerning prescription drugs.
(6) If a prescription drug order is delivered
to the patient or patient's agent or other designated location:
(a) the information in Subsection (3) shall
be delivered with the dispensed prescription in writing;
(b) if prescriptions are routinely delivered
outside the area covered by the pharmacy's local telephone service, the
pharmacist shall place on the prescription container or on a separate sheet
delivered with the prescription container, the telephone number of the pharmacy
and the statement "Written information about this prescription has been
provided for you. Please read this information before you take this medication.
If you have questions concerning this prescription, a pharmacist is available
during normal business hours to answer these questions."; and
(c) the written information under Subsection
(6)(b) shall be in the form of patient information leaflets similar to USP-NF
patient information monographs or equivalent information.
(7) Patient counseling is not required for
patients of a hospital or institution where other licensed health care
professionals are authorized to administer the patient's drugs.
(8) A pharmacist or pharmacy intern who
dispenses a self-administered hormonal contraceptive shall obtain a completed
Utah Hormonal Contraceptive Self-Screening Risk Assessment Questionnaire and
provide written information and counseling as described in Section
26-62-106.
